Inquiry Basket
MC-Val-Cit-PAB-Auristatin E is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.
| Catalog Number | Size | Price | Quantity | |
|---|---|---|---|---|
| BADC-00629 | -- | $-- | Inquiry |
MC-Val-Cit-PAB-Auristatin E is a conjugate designed for targeted cancer therapy, combining the potent cytotoxic agent Auristatin E with a targeting peptide and a linker system. Auristatin E, a derivative of the potent anti-tumor drug monomethyl auristatin E (MMAE), disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. The conjugation of Auristatin E to a peptide through the MC-Val-Cit-PAB linker ensures precise delivery of the cytotoxic payload to the tumor site, minimizing damage to healthy tissues and enhancing therapeutic efficacy.
One of the key applications of MC-Val-Cit-PAB-Auristatin E is in antibody-drug conjugates (ADCs) for targeted cancer therapy. The conjugate consists of a linker that connects Auristatin E to a peptide, which is capable of binding to specific cancer cell surface markers. This specificity allows the cytotoxic drug to be delivered directly to the tumor site, reducing off-target toxicity and enhancing the overall therapeutic index of the drug. By selectively targeting cancer cells, MC-Val-Cit-PAB-Auristatin E increases the localized concentration of the drug, improving its effectiveness while minimizing side effects often associated with conventional chemotherapy.
In addition to its role in ADCs, MC-Val-Cit-PAB-Auristatin E is also explored for its potential in overcoming drug resistance mechanisms in cancer therapy. Many cancers develop resistance to traditional chemotherapeutic agents, including those targeting the microtubule network. By using a targeted delivery system, MC-Val-Cit-PAB-Auristatin E can bypass some of the resistance mechanisms commonly seen in cancer cells. The linker system can help ensure that the cytotoxic drug is specifically delivered to tumor cells, improving treatment outcomes even in resistant cancer strains.
MC-Val-Cit-PAB-Auristatin E also plays a critical role in optimizing the pharmacokinetics of its payload. Traditional chemotherapeutic agents like Auristatin E can have poor solubility, limited bioavailability, and short half-lives in the body. The MC-Val-Cit-PAB linker improves the stability and solubility of Auristatin E, facilitating its controlled release at the target site. This controlled release helps to enhance the drug’s bioavailability and reduce systemic exposure, which is crucial for achieving a more effective and less toxic treatment regimen.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, non-natural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
